216 related articles for article (PubMed ID: 24282028)
1. Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease.
Ribeiro FM; Devries RA; Hamilton A; Guimaraes IM; Cregan SP; Pires RG; Ferguson SS
Hum Mol Genet; 2014 Apr; 23(8):2030-42. PubMed ID: 24282028
[TBL] [Abstract][Full Text] [Related]
2. Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity.
Giralt A; Puigdellívol M; Carretón O; Paoletti P; Valero J; Parra-Damas A; Saura CA; Alberch J; Ginés S
Hum Mol Genet; 2012 Mar; 21(6):1203-16. PubMed ID: 22116937
[TBL] [Abstract][Full Text] [Related]
3. Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease.
Ribeiro FM; Paquet M; Ferreira LT; Cregan T; Swan P; Cregan SP; Ferguson SS
J Neurosci; 2010 Jan; 30(1):316-24. PubMed ID: 20053912
[TBL] [Abstract][Full Text] [Related]
4. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
[TBL] [Abstract][Full Text] [Related]
5. Depletion of p62 reduces nuclear inclusions and paradoxically ameliorates disease phenotypes in Huntington's model mice.
Kurosawa M; Matsumoto G; Kino Y; Okuno M; Kurosawa-Yamada M; Washizu C; Taniguchi H; Nakaso K; Yanagawa T; Warabi E; Shimogori T; Sakurai T; Hattori N; Nukina N
Hum Mol Genet; 2015 Feb; 24(4):1092-105. PubMed ID: 25305080
[TBL] [Abstract][Full Text] [Related]
6. mGluR5 antagonism increases autophagy and prevents disease progression in the
Abd-Elrahman KS; Hamilton A; Hutchinson SR; Liu F; Russell RC; Ferguson SSG
Sci Signal; 2017 Dec; 10(510):. PubMed ID: 29259100
[TBL] [Abstract][Full Text] [Related]
7. Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington's pathology in zQ175 mice.
Abd-Elrahman KS; Ferguson SSG
Mol Brain; 2019 Apr; 12(1):35. PubMed ID: 30961637
[TBL] [Abstract][Full Text] [Related]
8. Metabotropic glutamate receptor 5 as a potential therapeutic target in Huntington's disease.
Ribeiro FM; Hamilton A; Doria JG; Guimaraes IM; Cregan SP; Ferguson SS
Expert Opin Ther Targets; 2014 Nov; 18(11):1293-304. PubMed ID: 25118797
[TBL] [Abstract][Full Text] [Related]
9. Involvement of mGlu5 receptor in 3-nitropropionic acid-induced oxidative stress in rat striatum.
Souza LC; Wilhelm EA; Bortolatto CF; Nogueira CW; Boeira SP; Jesse CR
Neurol Res; 2014 Sep; 36(9):833-40. PubMed ID: 24588139
[TBL] [Abstract][Full Text] [Related]
10. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease.
Smith GA; Rocha EM; McLean JR; Hayes MA; Izen SC; Isacson O; Hallett PJ
Hum Mol Genet; 2014 Sep; 23(17):4510-27. PubMed ID: 24728190
[TBL] [Abstract][Full Text] [Related]
11. Role of Dynein Axonemal Heavy Chain 6 Gene Expression as a Possible Biomarker for Huntington's Disease: a Translational Study.
Areal LB; Pereira LP; Ribeiro FM; Olmo IG; Muniz MR; do Carmo Rodrigues M; Costa PF; Martins-Silva C; Ferguson SSG; Guimarães DAM; Pires RGW
J Mol Neurosci; 2017 Dec; 63(3-4):342-348. PubMed ID: 29019003
[TBL] [Abstract][Full Text] [Related]
12. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.
Chan EY; Luthi-Carter R; Strand A; Solano SM; Hanson SA; DeJohn MM; Kooperberg C; Chase KO; DiFiglia M; Young AB; Leavitt BR; Cha JH; Aronin N; Hayden MR; Olson JM
Hum Mol Genet; 2002 Aug; 11(17):1939-51. PubMed ID: 12165556
[TBL] [Abstract][Full Text] [Related]
13. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease.
Doria JG; Silva FR; de Souza JM; Vieira LB; Carvalho TG; Reis HJ; Pereira GS; Dobransky T; Ribeiro FM
Br J Pharmacol; 2013 Jun; 169(4):909-21. PubMed ID: 23489026
[TBL] [Abstract][Full Text] [Related]
14. Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology.
Choudhury KR; Das S; Bhattacharyya NP
J Proteomics; 2016 Jan; 132():155-66. PubMed ID: 26581643
[TBL] [Abstract][Full Text] [Related]
15. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
[TBL] [Abstract][Full Text] [Related]
16. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease.
Schiefer J; Sprünken A; Puls C; Lüesse HG; Milkereit A; Milkereit E; Johann V; Kosinski CM
Brain Res; 2004 Sep; 1019(1-2):246-54. PubMed ID: 15306259
[TBL] [Abstract][Full Text] [Related]
17. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.
Blázquez C; Chiarlone A; Sagredo O; Aguado T; Pazos MR; Resel E; Palazuelos J; Julien B; Salazar M; Börner C; Benito C; Carrasco C; Diez-Zaera M; Paoletti P; Díaz-Hernández M; Ruiz C; Sendtner M; Lucas JJ; de Yébenes JG; Marsicano G; Monory K; Lutz B; Romero J; Alberch J; Ginés S; Kraus J; Fernández-Ruiz J; Galve-Roperh I; Guzmán M
Brain; 2011 Jan; 134(Pt 1):119-36. PubMed ID: 20929960
[TBL] [Abstract][Full Text] [Related]
18. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
Glynn D; Reim K; Brose N; Morton AJ
Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
[TBL] [Abstract][Full Text] [Related]
19. Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration.
Díaz-Hernández M; Díez-Zaera M; Sánchez-Nogueiro J; Gómez-Villafuertes R; Canals JM; Alberch J; Miras-Portugal MT; Lucas JJ
FASEB J; 2009 Jun; 23(6):1893-906. PubMed ID: 19171786
[TBL] [Abstract][Full Text] [Related]
20. Genetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesis.
Ryan AB; Zeitlin SO; Scrable H
Neurobiol Dis; 2006 Nov; 24(2):419-27. PubMed ID: 16978870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
